Breast Cancer Clinical Trial
Triple Negative Breast Cancer Biomarker Study
Summary
Patients with metastatic or locally recurrent triple negative breast cancer (TNBC) who are scheduled for medically indicated surgical biopsy or resection of disease will be identified. Fresh/frozen tissue will be collected and will undergo comprehensive molecular evaluation with NextGen sequencing. TGEN's clonal genomics analyses will be applied in the analysis to identify and prioritize the mutated targets. Therapeutic options, based on the genetic profile of each patient's tumor, will be discussed and an appropriate molecularly-selected agent will be recommended by the Study Investigator(s) (SI) and treating oncologist as treatment for the patient.
This is an open-label, pilot trial. Patients with metastatic or locally recurrent TNBC who are scheduled for medically indicated surgical biopsy or resection will be enrolled and therapeutic options, based on the genetic profile of each patient's tumor, will be discussed with the patient.
Time-to-progression (TTP) for these patients following the selected therapy is the primary objective and will be compared to the TTP(s) for their most recent prior therapy. A 30% increase in TTP with the molecularly-targeted agent compared with the TTP on the immediate prior therapy will be considered as evidence of clinical benefit from the selected therapy. The secondary endpoints are best response to the molecularly-selected therapy, overall survival (OS) and genetic mutation evaluation in metastatic (or locally recurrent) TNBC.
The study is designed to demonstrate that the collection and analysis of these tumor samples is feasible.
Eligibility Criteria
Inclusion Criteria:
Has metastatic or locally recurrent triple negative breast cancer and is scheduled for medically indicated surgical biopsy or resection of disease
Will have measurable or evaluable (nonmeasurable) disease per RECIST v 1.1 (see Section 10) present after surgical biopsy/resection. Note: following surgical resection, if the tumor sample is found to be inadequate for comprehensive molecular analysis, the patient will be deemed ineligible and will be replaced.
Has received at least 1 prior chemotherapeutic regimen for their metastatic or locally recurrent TNBC prior to initiating the molecularly-selected therapy. There is no limit on the prior therapy for TNBC. Note: We strongly recommend holding of on intervening therapy if possible from the time of biopsy to the completion of sequencing so as not to change the cancer under the selective pressure of treatment, so that the sequencing results are reflective of the current cancer.
Is at least 18 years of age
Has an expected survival of at least 6 months, as estimated by the treating oncologist
Has planned surgical resection (indicated for the medical care of the patient) that will yield a minimum fresh/frozen tumor sample of 1 cm x 1 cm x 1 cm (~300 mg) that will be available for molecular profiling analysis.
Is agreeable to having a blood sample (10-20 mL) drawn and analyzed to compare their normal genetic profile to that of their tumor sample
Has signed the most recent Patient Informed Consent Form
Has signed a Patient Authorization Form
Exclusion Criteria:
Has breast cancer other than metastatic or locally recurrent TNBC. Note: surgical resection of the recurrent TNBC will render the patient as "no evidence of disease" (NED). NED patients are ineligible and will be replaced.
Has a history of heart disease, other conditions that would prevent treatment with a standard chemotherapeutic agent
Has evidence of central nervous system (CNS) involvement that is progressing or that requires radiation, resection or steroid therapy
Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection
Is a pregnant or nursing woman
Is unable to comply with requirements of study
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 18 Locations for this study
Denver Colorado, 80220, United States
Elizabeth City North Carolina, 27909, United States
Portland Oregon, 97213, United States
Portland Oregon, 97225, United States
Portland Oregon, 97227, United States
Tualatin Oregon, 97062, United States
Dallas Texas, 75231, United States
Dallas Texas, 75246, United States
Houston Texas, 77024, United States
Tyler Texas, 75702, United States
Chesapeake Virginia, 23320, United States
Hampton Virginia, 23666, United States
Newport News Virginia, 23606, United States
Norfolk Virginia, 23502, United States
Virginia Beach Virginia, 23456, United States
Williamsburg Virginia, 23188, United States
Vancouver Washington, 98684, United States
Vancouver Washington, 98686, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.